The World Health Organization (WHO) has officially recommended the use of lenacapavir, a twice-yearly injectable pre-exposure ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The World Health Organization (WHO) on Monday recommended countries to use the twice-a-year lenacapavir injection as an add ...

This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...